ArticleNature communications2019
m
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 480 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
480citing papers in PubMed, 1 pooled it
39.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
480 citing papers in PubMed, 1 synthesis or guideline pooled it, 810 citations in OpenAlex.
- Global research trends in mFrontiers in genetics · 2026Pooled it
- Rho GTPase-driven stress granules enable anchorage-independent survival under adhesion stress.Research square · 2026Article
- Regulatory roles of N6-methyladenosine methylation factors in melanoma invasion and metastasis (Review).Oncology letters · 2026Review
- A targetable FTO/SLC7A11/CBS/CTH axis controls cysteine metabolism, growth and survival in NSCLC.Science advances · 2026Article
- Fat Mass and Obesity-Associated Protein Contributes to Tumorigenesis and Drug Resistance of Diffuse Large B-Cell Lymphoma by Suppressing N6-Methyladenosine Methylation of Myc.The Kaohsiung journal of medical sciences · 2026Article
- mClinical and translational medicine · 2026Article
- Epigenetic plasticity in cancer drug resistance: mechanistic insights and strategies for therapeutic intervention.Acta pharmacologica Sinica · 2026Review
- Inhibition of YTHDF2-mediated CYLD mRNA degradation promotes neuronal ferroptosis and pain in Parkinson's disease through NOX4 deubiquitination.Cell biology and toxicology · 2026Article
- The crucial role of m6A methylation modification in nasopharyngeal carcinoma.Discover oncology · 2026Review
- cGAMP suppresses FTO expression to promote mCellular and molecular life sciences : CMLS · 2026Article
- mRNA-based melanoma vaccines targeting gp100 and TRP2 macromolecules.Discover oncology · 2026Review
- RNA modifications and cancer ferroptosis.Cancer cell international · 2026Review
- Reduced YTHDF2 inhibits PD-L1 expression by stabilizing mCell death & disease · 2026Article
- FTO-ACKR3 Axis Regulates Polycyclic Aromatic Hydrocarbons-Induced Asthma Attacks via AhR-Mediated mEnvironment & health (Washington, D.C.) · 2026Article
- Mechanisms and therapeutic potential of YTHDF readers: Linking epitranscriptomics to cancer.Journal of pharmaceutical analysis · 2026Review
- Targeting intracellular mRNA mJournal of advanced research · 2026Review
- Targeting epigenetic methylation: emerging diagnosis and therapeutic strategies in cancer.Experimental hematology & oncology · 2026Review
- NNature reviews. Cancer · 2026Review
- Long noncoding RNA PCAT7 confers radioresistance of esophageal squamous cell carcinoma by promoting GCLM-mediated anti-ferroptosis.Journal of translational medicine · 2026Article
- Epitranscriptomic control of cancer hallmarks: Functions, mechanisms, and therapeutics of RNA modifications.Cancer cell · 2026Review
420 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Seungwon YangDepartment of Medicine, Section of Dermatology, University of Chicago, Chicago, IL, 60637, USA.ORCID http://orcid.org/0000-0002-8970-7373
Jiangbo WeiDepartments of Chemistry, Department of Biochemistry and Molecular Biology, Institute for Biophysical Dynamics, University of Chicago, Chicago, IL, 60637, USA.
Yan-Hong CuiDepartment of Medicine, Section of Dermatology, University of Chicago, Chicago, IL, 60637, USA.
Gayoung ParkDepartment of Pathology, University of Chicago, Chicago, IL, 60637, USA.
Palak ShahDepartment of Medicine, Section of Dermatology, University of Chicago, Chicago, IL, 60637, USA.ORCID http://orcid.org/0000-0002-6142-5630
Yu DengDepartment of Medicine, Section of Dermatology, University of Chicago, Chicago, IL, 60637, USA.ORCID http://orcid.org/0000-0003-2292-2957
Andrew E AplinDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, 19107, USA.ORCID http://orcid.org/0000-0002-2734-3244
Zhike LuDepartments of Chemistry, Department of Biochemistry and Molecular Biology, Institute for Biophysical Dynamics, University of Chicago, Chicago, IL, 60637, USA.
Seungmin HwangDepartment of Pathology, University of Chicago, Chicago, IL, 60637, USA.ORCID http://orcid.org/0000-0003-0846-5462
Chuan HeDepartments of Chemistry, Department of Biochemistry and Molecular Biology, Institute for Biophysical Dynamics, University of Chicago, Chicago, IL, 60637, USA. chuanhe@uchicago.edu.ORCID http://orcid.org/0000-0003-4319-7424
Yu-Ying HeDepartment of Medicine, Section of Dermatology, University of Chicago, Chicago, IL, 60637, USA. yyhe@medicine.bsd.uchicago.edu.ORCID http://orcid.org/0000-0002-2665-7962
University of Chicago · USHoward Hughes Medical Institute · USThomas Jefferson University · US
Funding
VIRAL ONCOLOGY CORE FACILITYP30CA014599 · NCI · UNIVERSITY OF CHICAGO · PI MARK W. LINGEN · 1985 to 2026
$122.1MRe-Engineering Translational Research at the University of ChicagoUL1TR000430 · NCATS · UNIVERSITY OF CHICAGO · PI SOLWAY, JULIAN · 2012 to 2016
$20.2MPilot Program CoreP30ES027792 · NIEHS · UNIVERSITY OF CHICAGO · PI Gokhan M. Mutlu, Gail S Prins · 2017 to 2026
$13.6MYTHDF2 and UVB damage response in skin cancerR01ES024373 · NIEHS · UNIVERSITY OF CHICAGO · PI HE, YU-YING · 2015 to 2023
$4.3MThe mechanistic role of METTL14 in UVB-induced skin tumorigenesisR01ES030576 · NIEHS · UNIVERSITY OF CHICAGO · PI HE, YU-YING · 2019 to 2023
$3.0MDirect Oxidative Nucleic Acids DemethylationR01ES030546 · NIEHS · UNIVERSITY OF CHICAGO · PI HE, CHUAN · 2019 to 2023
$1.9MMutant BRAF-regulated transcription factors in melanoma progressionR01CA196278 · NCI · THOMAS JEFFERSON UNIVERSITY · PI APLIN, ANDREW ERIC · 2015 to 2019
$1.8MTargeting by autophagy proteins for anti-tumor immunityDP2CA225208 · NCI · UNIVERSITY OF CHICAGO · PI HWANG, SEUNGMIN · 2017 to 2017
$510kNCATS NIH HHS UL1 TR000430NCI NIH HHS DP2 CA225208NCI NIH HHS P30 CA014599NCI NIH HHS R01 CA196278NIEHS NIH HHS P30 ES027792NIEHS NIH HHS R01 ES024373NIEHS NIH HHS R01 ES030546NIEHS NIH HHS R01 ES030576
Abstract
Melanoma is one of the most deadly and therapy-resistant cancers. Here we show that N
Indexed as
AdenosineAlpha-Ketoglutarate-Dependent Dioxygenase FTOAnimalsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedCarcinogenesisCell Line, TumorCell ProliferationDemethylationDNA MethylationFemaleHumansImmunotherapyMelanomaMiceMice, Inbred C57BLAdenosineAlpha-Ketoglutarate-Dependent Dioxygenase FTOAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedatezolizumabFTO protein, humanFTO protein, mouseN-methyladenosineProgrammed Cell Death 1 ReceptorRNA, Messenger
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.